ONC Key Statistics, Chart & Performance
The current stock price of ONC is 312.39 USD. In the past month the price decreased by -8.29%.
ONC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About ONC
Company Profile
BeOne Medicines AG is a CH-based company operating in Biotechnology industry. The company is headquartered in Basel, Basel-Stadt and currently employs 11,075 full-time employees. The company went IPO on 2016-03-02. BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. The company is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Company Info
BEONE MEDICINES LTD-ADR
c/o BeOne Medicines I GmbH, Aeschengraben 27
Basel BASEL-STADT CH
Employees: 11000
Phone: 41616851900
BEONE MEDICINES LTD-ADR / ONC FAQ
What does BEONE MEDICINES LTD-ADR do?
BeOne Medicines AG is a CH-based company operating in Biotechnology industry. The company is headquartered in Basel, Basel-Stadt and currently employs 11,075 full-time employees. The company went IPO on 2016-03-02. BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. The company is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Can you provide the latest stock price for BEONE MEDICINES LTD-ADR?
The current stock price of ONC is 312.39 USD. The price increased by 0.21% in the last trading session.
Does BEONE MEDICINES LTD-ADR pay dividends?
ONC does not pay a dividend.
What is the ChartMill technical and fundamental rating of ONC stock?
ONC has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Which stock exchange lists ONC stock?
ONC stock is listed on the Nasdaq exchange.
What is the outstanding short interest for BEONE MEDICINES LTD-ADR?
The outstanding short interest for BEONE MEDICINES LTD-ADR (ONC) is 19.07% of its float.
ONC Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ONC.
ONC Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to ONC. The financial health of ONC is average, but there are quite some concerns on its profitability.
ONC Financial Highlights
Over the last trailing twelve months ONC reported a non-GAAP Earnings per Share(EPS) of 64.43. The EPS increased by 215.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3.68% | ||
| ROE | -6.15% | ||
| Debt/Equity | 0.26 |
ONC Forecast & Estimates
16 analysts have analysed ONC and the average price target is 335.18 USD. This implies a price increase of 7.3% is expected in the next year compared to the current price of 312.39.
For the next year, analysts expect an EPS growth of 139.04% and a revenue growth 41.33% for ONC